Data / Form D filings / Akelos, Inc.
Akelos, Inc.: Form D filings
Akelos, Inc., a biotechnology company in New York, NY, filed 4 Form D notices with the SEC between 2018 and 2026. The latest, on March 16, 2026, reports $1.5 million sold of an offering with no set size to 81 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 215 EAST 68TH STREET, SUITE 26B, New York, NY, 10065
- Phone
- (212) 953-1544
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(c)
- SEC identifier (CIK)
- 1760186
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | New notice | Indefinite | $1,486,000 | 81 | Mar 9, 2026 | sec.gov | |
| Oct 28, 2022 | New notice | $14,000,000 | $5,500 | $13,994,500 | 1 | Oct 21, 2022 | sec.gov |
| Feb 5, 2019 | New notice | $3,000,000 | $25,000 | $2,975,000 | 1 | Jan 31, 2019 | sec.gov |
| Nov 28, 2018 | New notice | $295,000 | $295,000 | 12 | Oct 23, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Steven Fox | Executive Officer |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of Mar 16, 2026 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Akelos, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.